Treatment Experience Blueprint
Nuvera Life Science Consulting
Greg Klein, Managing Partner
contact@nuveracg.com
The Treatment Experience Blueprint is an industry recognized, innovative methodology and organizational planning tool developed by Nuvera Life Science Consulting, an Ashfield Engage company. This foundational document defines and aligns patient, care partner, and HCP needs with organizational capabilities to deliver an enhanced treatment experience. This provides huge value in the demanding healthcare landscapes served by specialty pharmaceutical, biotech, and rare disease companies working in neuroscience, oncology, hematology, respiratory, dermatology, cardiovascular, immunology, and cell and gene therapy.
The Treatment Experience Blueprint works to clearly align the cross functional teams within a life sciences company around a consistent understanding, focus, and development of strategic and tactical plans that build the capabilities for putting the patient front and center. The process includes four key elements:
- Integration of existing data inclusive of market research, brand strategy, market insight, competitive information, and field information and examining all touchpoints to enable visibility of how all treatment components interconnect, creating a “single version of the truth.”
- Clarification by highlighting the challenges, moments that matter, and key pain points along the patient journey.
- Identification and prioritization of opportunities and solutions that deliver a consistent and positive support experience aligned to critical brand considerations.
- Alignment of the organization cross functionally, prioritizing the tackling of initiatives from quick wins to longer term strategic solutions.
Navigating cell and gene therapy and specialty treatment areas starts with the therapy or product, but requires a seamless patient experience to be successful. The Treatment Experience Blueprint, built on Nuvera’s deep experience in architecting seamless customer experiences, provides this holistic approach while helping pharma prioritize where to invest its time and money.
